[Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. I. Effect on cholesterol, lipid and apoprotein levels].

Abstract

The effects of a new fibric acid derivative--beclobrate (Turec, Zyma) on serum lipid and apoprotein concentrations in 63 patients with primary hyperlipoproteinemia were examined. Beclobrate was given in the evening, 100 mg, once daily. After 3 months of beclobrate treatment mean total cholesterol concentration in serum decreased from 9.35 to 7.73 mmol/l (17.3%), mean LDL-cholesterol concentration from 6.32 to 5.38 mmol/l (14.9%), mean HDL-cholesterol concentration increased by 0.21 mmol/l (15.3% of initial value). The greatest decrease was observed in triglyceride concentration--by 50% of the initial value. Apoprotein B concentration decreased by 19.7%, apoprotein A1 and A2 concentration increased by 20.3% and 26.8% respectively. Higher initial values of total cholesterol and triglyceride concentration in serum were associated with greater concentration decrease after beclobrate treatment.

• Authors: J Sznajd, B Idzior-Waluś, J Zabiński, I Wybrańska, G Korzus, J Iwanejko
• Journal: Przeglad lekarski (Przegl Lek) Vol. 47 Issue 10 Pg. 706-10 ( 1990) ISSN: 0033-2240 [Print] Poland
• Vernacular Title: Beklobrat (Turec) w leczeniu pierwotnej hiperlipoproteinemii. Cześć I: Wpływ na stezenie cholesterolu, lipidy i apoproteiny.
• PMID: 2089449 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Apoproteins
• Benzhydryl Compounds
• Hypolipidemic Agents
• Lipids
• beclobrate

Topics

• Adolescent
• Adult
• Aged
• Apoproteins (blood)
• Benzhydryl Compounds (therapeutic use)
• Humans
• Hypercholesterolemia (drug therapy)
• Hypertriglyceridemia (drug therapy)
• Hypolipidemic Agents (therapeutic use)
• Lipids (blood)
• Middle Aged